التفاصيل البيبلوغرافية
| العنوان: |
C‐C chemokine receptor 4 expression in CD8+ cutaneous T‐cell lymphomas and lymphoproliferative disorders, and its implications for diagnosis and treatment. |
| المؤلفون: |
Geller, Shamir1,2 (AUTHOR) shamirgeller@gmail.com, Hollmann, Travis J3 (AUTHOR), Horwitz, Steven M4 (AUTHOR), Myskowski, Patricia L1 (AUTHOR), Pulitzer, Melissa3 (AUTHOR) |
| المصدر: |
Histopathology. Jan2020, Vol. 76 Issue 2, p222-232. 11p. 1 Color Photograph, 1 Diagram, 2 Charts. |
| مصطلحات موضوعية: |
*MYCOSIS fungoides, *LYMPHOPROLIFERATIVE disorders, *CHEMOKINE receptors, *LYMPHOMAS, *CYTOTOXIC T cells, *T-cell lymphoma, *RITUXIMAB, *CUTANEOUS T-cell lymphoma |
| مستخلص: |
Aims: Patients with aggressive CD8+ cutaneous T‐cell lymphomas (CTCLs) progress rapidly and respond poorly to therapy. Confounding treatment planning, there is clinicopathological overlap between aggressive CD8+ CTCLs and other lymphoproliferative disorders (LPDs). Hence, improved diagnostic methods and therapeutic options are needed. The aim of this study was to examine C‐C chemokine receptor 4 (CCR4) expression as a diagnostic and therapeutic biomarker in CD8+ CTCLs/LPDs. Methods and results: Forty‐nine cases (41 patients) with CD8+ CTCLs/LPDs were examined, including CD8+ mycosis fungoides (MF) (n = 14), aggressive epidermotropic CD8+ cytotoxic T‐cell lymphoma (AETCL) (n = 8), subcutaneous panniculitis‐like T‐cell lymphoma (SPTCL) (n = 7), CD30+ LPDs (n = 6), primary cutaneous γδ T‐cell lymphoma (GDTCL) (n = 6), and others (n = 8). Immunohistochemical tissue staining was performed with a CCR4 monoclonal antibody on formalin‐fixed paraffin‐embedded tissue sections. CCR4 immunostaining was graded as percentage infiltrate, i.e. high (>25%) and low (≤25%), and the results were correlated with clinicopathological diagnoses. CCR4 expression was seen in 69% of the studied cases. Any CCR4 positivity was seen in all CD8+ MF cases, in 83% of CD30+ LPD cases, in 75% of AETCL cases, in 33% of GDTCL cases, and in none of the SPTCL cases. High CCR4 expression was seen in 79% of CD8+ MF cases versus 33% of CD30+ LPD cases, in 17% of GDTCL cases, and in 12.5% of AETCL cases. Patients with more advanced MF stage had higher CCR4 expression. Conclusions: CCR4 immunohistochemistry may be an adjunct in distinguishing advanced CD8+ MF from other CD8+ CTCLs/LPDs. Although CCR4 expression may justify therapeutic targeting of this receptor in CD8+ MF, the role of such therapies in other CD8+ CTCLs/LPDs is not yet clear. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
